US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.24 against a street estimate of 0.23 — a beat of 4.3%.
Analysts rate Amneal Pharmaceuticals, Inc. Class A Common Stock a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $23.43.
CONFIDENT Amneal delivered Q2 revenue of $796M (+10% YoY), adjusted EBITDA of $206M (+12%), adjusted EPS of $0.30 (+20%). Raised full-year 2026 guidance. Core growth drivers: Affordable Medicines pipeline (lanreotide, iohexol), Specialty brands (CREXONT, BREKIYA), pending Kashiv biosimilar acquisition, and GLP-1 partnership with Pfizer. Q2 2026 One India facility disrupted by Gujarat flooding one week prior; limited impact on select products; resumption expected within weeks. Included $20M estimated negative impact in raised 2026 guidance. Analysts pressed on lanreotide/XOLAIR launch timing, iohexol revenue buildout, and Specialty M&A strategy. Management confirmed lanreotide Q3 target with inventory ready, iohexol revenue deferred to 2027, and Specialty focus shifting post-Kashiv with CNS/oncology opportunities under review. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.63% |
| TPG GP A, LLC | 3.54% |
| Vanguard Portfolio Management, LLC | 3.48% |
| Rubric Capital Management LP | 2.92% |
| Vanguard Capital Management, LLC | 2.21% |
| State Street Corp | 2.11% |
| Dimensional Fund Advisors, Inc. | 1.66% |
| Geode Capital Management, LLC | 1.48% |
| Document | Date |
|---|---|
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net revenue was $863 million, up 10% from $785 million in Q3 2025. • GAAP net loss attributable to Amneal was $22 million | 2026-11-03 |
| Material agreement · Q3 2026 AMNEAL PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Upfront Cash Payment: $375,000,000 paid to acquire Kashiv BioSciences, LLC • Stoc | 2026-08-10 |
| Quarterly report · Q2 2026 AMNEAL PHARMACEUTICALS, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Revenue Q2 2026: $796.2 million (up 9.9% vs. Q2 2025: $724.5 million) • N | 2026-08-06 |
| Material agreement · Q3 2026 AMNEAL PHARMACEUTICALS, INC. - FORM 8-K SUMMARY August 3, 2026 --- HEADLINE NUMBERS • Total term loan debt after repricing: $2.084 billion ($2.039 | 2026-08-03 |
| Shareholder vote results · Q3 2026 AMNEAL PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Transaction value: Amneal acquiring 100% of Kashiv BioSciences, LLC membership in | 2026-07-31 |
| Results announced · Q3 2026 AMNEAL PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 net revenue: $796 million (up 10% vs. $725 million in Q2 2025) • GAAP ne | 2026-07-30 |
| Quarterly report · Q1 2026 AMNEAL PHARMACEUTICALS, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net revenue Q1 2026: $722.5 million (vs. $695.4 million Q1 2025) — increase o | 2026-05-07 |
| Proxy statement · Q2 2026 AMNEAL PHARMACEUTICALS, INC. – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect 10 directors nominated by the Board | 2026-03-25 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completed acquisition; amended stockholders agreement and credit facilities Amneal Pharmaceuticals completed an acquisition (of Kashiv Pharma) on August 10, 2026. To finance this deal, the company borrowed $350 million through a new incremental term loan from Bank o | 2026-08-10 |
| Stockholders approve acquisition of Kashiv BioSciences membership interests Amneal Pharmaceuticals held a shareholder vote on July 31, 2026, to approve its acquisition of Kashiv BioSciences. Both key proposals passed with strong support: Proposal 1 (approval of the | 2026-07-31 |
| Company announces acquisition; hosts conference call and investor presentation Amneal Pharmaceuticals announced a significant acquisition of Kashiv Biosciences on April 21-22, 2026. The company moved up its earnings call to April 22 at 8:30 AM ET to discuss the deal an | 2026-04-22 |
| Expects to meet or exceed 2025 full-year financial guidance Amneal Pharmaceuticals announced it expects to meet or exceed its 2025 full-year financial guidance. Key financial targets include net revenue of $3.0-$3.1 billion, adjusted EBITDA of $675-$ | 2026-01-13 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Amneal Pharmaceuticals, Inc. Class A Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.